History

2002

Advanced Accelerator Applications (AAA) is created as a “spin-off” of the CERN.

2003

Construction of AAA’s first radiopharmaceutical laboratory in the Technoparc of Saint-Genis-Pouilly (Rhône-Alpes, France).

2004

First Marketing Authorization from the Swiss Authorities to commercialize GLUSCAN® in Switzerland.

2006

AAA completes the construction of its second radiopharmaceutical production plant in Venafro (Molise, Italy).

2007

AAA completes the construction of its third radiopharmaceutical production plant in the Bioindustry park of Canavese (Ivrea, Piedmont, Italy).

2008

AAA completes the construction of its fourth radiopharmaceutical production plant in Troyes (France) to produce GLUSCAN® and PET Investigational Medical Products (IMPs).

2008

AAA completes the construction of its fifth radiopharmaceutical production plant in Béthune (France) to produce GLUSCAN® and PET Investigational Medical Products (IMPs).

2008

Exclusive license agreement signed with Bracco for Cardiogen® (Sr-Rb generator for Cardiac PET) distribution in Europe.

2009

Completed the acquisition of Gipharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products.

2009

AAA starts building two more radiopharmaceuticals production plants: one in Meldola (Forlì, Italy) and one in “La Almunia de Doña Godina” (Zaragoza, Spain). Licence contract signed with IASON.

2010

Initial equity investment in Atreus Pharmaceuticals Corporation (located in Ottawa, Canada).

2010

AAA acquires BioSynthema Inc. (located in St. Louis, Missouri, USA), a molecular nuclear medicine discovery company.

2011

AAA raises €40 million from existing and new investors to progress and expand the pipeline and invest in the expansion of the Company’s PET manufacturing network.

2011

Acquisition of FabOvar and third party manufacturing agreement with GE Healthcare.

2011

Completion of the Forli facility and La Almunia de Doña Godina (Zaragoza, Spain).

2012

AAA initiates phase III pivotal trial for Lutathera®.

2012

AAA obtains first its direct presence in Germany with the acquisition of a 50.1% stake in Umbra Medical AG.

2012

AAA’S 10 YEAR ANNIVERSARY. A decade of innovation and growth.

2012

AAA acquires a fully operational PET production laboratory in Porto, Portugal.

2012

AAA further strengthens its position in Spain with the acquisition of Barnatron and Catalana De Dispensación, S.A.

2013

AAA signs new PET manufacturing agreements with Eli Lilly and GE Healthcare.

2013

AAA enters the Polish market following an agreement with the University of Warsaw.

2013

AAA finalizes the construction of its new headquarter building in Saint-Genis-Pouilly.

2014

AAA raises €41 million to accelerate international expansion, including an increased presence in the US, and help finance clinical trials.

2014

AAA receives orphan drug designation from FDA and EMA for Gallium-68 DOTATATE.

2014

AAA obtains its first direct presence in the UK and Irish markets with the acquisition of Imaging Equipment Ltd (IEL).

2014

AAA establishes a Delaware corporation with an office in the Empire State Building in New York.

2014

AAA starts commercial operations in 3 new production sites: Warsaw, Bonn, Marseille.

2015

AAA completes €23 million crossover financing with US-based institutions. US investors include: Adage Capital Management LP, T. Rowe Price, and Rock Springs Capital Management LP.

2015

AAA announces results from Phase III NETTER-1 evaluating 177Lutetium Dotatate in patients with advanced midgut neuroendocrine tumors at the ECC 2015.

2015

AAA goes public and starts trading on the Nasdaq Global Select Market on 11 November 2015 under the ticker “AAAP”.

2016

AAA acquires the IDB Group. The transaction expands AAA’s global supply chain in preparation for the commercial launch of Lutathera.

2016

AAA signs exclusive license agreement with Johns Hopkins University to develop PSMA receptor ligand in prostate cancer. The Company broadens pipeline with PSMA-R2, which could be used to treat, image, monitor and stage prostate cancer utilizing a clinical development strategy similar to Lutathera and Somakit.

2016

Lutathera Expanded Access Program opened in US to eligible patients.

2016

AAA expands its presence in Germany with acquisition of two production sites in Erlangen and Munich.

2016

FDA approval of NETSPOT (Somakit-TATE) and European Commission approval of SomaKit TOC, kits for the preparation of Gallium Ga 68 Dotatate for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.

2016

Expansion of AAA’s theranostic pipeline with NeoBOMB1, a novel antagonist bombesin analogue that selectively binds to GRPR receptors (indications include GIST, prostate and breast cancers).